Last updated: 11/04/2018 03:57:46

Evaluation of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine in young males.

Request patient level data
GSK study ID
580299/011
See study documents
Clinicaltrials.gov ID
NCT00309166
See results summary
EudraCT ID
2005-005943-24
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: An observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years
Trial description: The main aim of this vaccine is to prevent cervical cancer in women. However, it could also be relevant to vaccinate selected groups of males. Therefore, this study is designed to evaluate the safety and immunogenicity of the HPV vaccine in pre-teen and adolescent male subjects aged 10-18 years.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:

Number of seroconverted subjects for anti-HPV-16 and anti-HPV-18

Timeframe: At Month 7

Antibody titers against HPV-16 (anti-HPV-16) and HPV-18 (anti-HPV-18)

Timeframe: At Month 7

Secondary outcomes:

Number of seroconverted subjects for anti-HPV-16 and anti-HPV-18

Timeframe: At Month 2

Antibody titers against HPV-16 (anti-HPV-16) and HPV-18 (anti-HPV-18)

Timeframe: At Month 2

Number of subjects with any and Grade 3 solicited local symptoms

Timeframe: Within 7 days (Days 0-6) after each dose and across doses, up to 7 months

Number of subjects with any, Grade 3 and related solicited general symptoms

Timeframe: Within 7 days (Days 0-6) after each dose and across doses, up to 7 months

Number of subjects with any, Grade 3 and related unsolicited adverse events (AEs)

Timeframe: Within 30 days (Day 0-29) after any vaccination, up to 7 months

Number of subjects with new onset of chronic diseases (NOCDs) and other medically significant conditions

Timeframe: Throughout the active phase of the study (up to Month 7) and the extended safety follow-up (from Month 7 up to Month 12)

Number of subjects with serious adverse events (SAEs)

Timeframe: Throughout the active phase of the study (up to Month 7) and the extended safety follow-up (from Month 7 up to Month 12)

Number of subjects with clinically relevant abnormalities in biochemical and haematological parameters

Timeframe: At Month 2 and Month 7, post-vaccination

Number of subjects with clinically relevant abnormalities in biochemical and haematological parameters

Timeframe: At Month 2 and at Month 7, post-vaccination

Interventions:
Biological/vaccine: Cervarix vaccine
Biological/vaccine: Engerix-B vaccine
Enrollment:
270
Observational study model:
Not applicable
Primary completion date:
2007-19-06
Time perspective:
Not applicable
Clinical publications:
Petäjä T et al. (2009) Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years. J Adolesc Health. 44(1): 33–40.
Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638.
Medical condition
Infections, Papillomavirus
Product
SB580299, SKF103860
Collaborators
Not applicable
Study date(s)
April 2006 to June 2007
Type
Interventional
Phase
2

Participation criteria

Sex
Male
Age
10 - 18 years
Accepts healthy volunteers
Yes
  • A male between, and including, 10 and 18 years of age at the time of the first vaccination.
  • Written informed consent obtained from the subject prior to enrolment
  • Previous vaccination against Human Papillomavirus (HPV).
  • Previous vaccination against Hepatitis B, known clinical history of Hepatitis B infection.
Inclusion and exclusion criteria
Inclusion criteria:

    A male between, and including, 10 and 18 years of age at the time of the first vaccination.

    • Written informed consent obtained from the subject prior to enrolment
    • For subjects below the legal age of consent, a written informed consent must be obtained from the subject’s parent/guardian. In addition, a written informed assent must be obtained from the subject.
    • Healthy subjects as established by medical history and clinical examination before entering into the study.
    • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
Exclusion criteria:

    Previous vaccination against Human Papillomavirus (HPV).

    • Previous vaccination against Hepatitis B, known clinical history of Hepatitis B infection.
    • Cancer or autoimmune disease under treatment.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Tampere, Finland, 33200
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rauma, Finland, 26100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mikkeli, Finland, 50100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kouvola, Finland, 45100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kotka, Finland, 48100
Status
Study Complete
Contact us

Study documents

Clinical study report
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2007-19-06
Actual study completion date
2007-19-06

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click here
Access to clinical trial data by researchers
Visit website